AW/EPOPD 02
Alternative Names: AW-EPOPD02; AW/EPOPD-02Latest Information Update: 05 Sep 2023
Price :
$50 *
At a glance
- Originator INOXIA Lifesciences
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action Peroxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Ulcerative colitis
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Asthma in Austria (unspecified route)
- 05 Sep 2023 Discontinued - Preclinical for Ulcerative colitis in Austria (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Asthma in Austria